文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

高剂量巴氯芬对接受机械通气的有害酒精使用患者激越相关事件的影响:一项随机临床试验

Effect of High-Dose Baclofen on Agitation-Related Events Among Patients With Unhealthy Alcohol Use Receiving Mechanical Ventilation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

这项在法国18个ICU开展的3期双盲安慰剂对照随机临床试验,纳入314例接受机械通气的有害酒精使用成人患者,评估高剂量巴氯芬(50-150 mg/日)与安慰剂相比对激越相关事件的影响。结果显示巴氯芬组至少发生1次激越相关事件的患者比例显著降低(19.7% vs 29.7%),但机械通气时间和ICU住院时间显著延长,28天死亡率无显著差异,延迟觉醒更常见。

要点

  • 高剂量巴氯芬可显著降低机械通气有害酒精使用患者的激越相关事件比例。
  • 巴氯芬组机械通气时间和ICU住院时间显著延长,延迟觉醒发生率更高。
  • 28天死亡率两组无显著差异,巴氯芬在此场景中的作用尚需进一步研究。

核心结论

  • 在有害酒精使用并接受机械通气的患者中,高剂量巴氯芬较安慰剂显著减少激越相关事件,但效应 modest,且次要终点和不良事件总体结果提示需进一步研究以确定其作用并优化剂量。

研究设计与样本

  • 3期、双盲、安慰剂对照随机临床试验,在法国18个ICU开展,2016年6月至2018年2月入组,末次随访2019年5月。
  • 共随机314例接受机械通气的有害酒精使用成人患者,巴氯芬组159例,安慰剂组155例,313例(99.7%)完成试验。
  • 巴氯芬剂量根据估算肾小球滤过率从50至150 mg/日调整,机械通气期间使用最长15天,随后3至6天逐渐减量。

主要发现

  • 巴氯芬组至少发生1次激越相关事件的患者比例为19.7%(31例),安慰剂组为29.7%(46例),差异-9.93%(95%CI -19.45%至-0.42%),调整比值比0.59(95%CI 0.35-0.99)。
  • 巴氯芬组机械通气中位时间显著长于安慰剂组(9天 vs 8天;差异2.00天,95%CI 0.00-3.00;拔管风险比0.76,95%CI 0.60-0.97)。
  • 巴氯芬组ICU住院中位时间显著长于安慰剂组(14天 vs 11天;差异2.00天,95%CI 0.00-4.00;出院风险比0.70,95%CI 0.54-0.90)。
  • 28天死亡率巴氯芬组25.3%,安慰剂组21.6%,调整比值比1.24(95%CI 0.72-2.13),无显著差异。
  • 延迟觉醒(停用镇静镇痛药后72小时无睁眼)巴氯芬组14例(8.9%),安慰剂组3例(1.9%)。

关键数值与推荐

  • 主要终点为治疗期间至少发生1次激越相关事件的患者百分比。
  • 18个预设次要终点中14个无显著差异。

临床怎么用

  • 对于有害酒精使用并接受机械通气的患者,高剂量巴氯芬可减少激越相关事件,但需权衡机械通气及ICU住院时间延长和延迟觉醒风险。
  • 鉴于效应 modest 及次要终点和不良事件总体结果,巴氯芬在该场景中的作用尚需进一步研究确定并优化剂量。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Unhealthy alcohol use can lead to agitation in the intensive care unit (ICU). OBJECTIVE: To assess whether high-dose baclofen reduces agitation-related events compared with placebo in patients with unhealthy alcohol use receiving mechanical ventilation. DESIGN, SETTINGS, AND PARTICIPANTS: This phase 3, double-blind, placebo-controlled, randomized clinical trial conducted in 18 ICUs in France recruited adults receiving mechanical ventilation who met criteria for unhealthy alcohol use. Patients were enrolled from June 2016 to February 2018; the last follow-up was in May 2019. INTERVENTIONS: Baclofen (n = 159), adjusted from 50 to 150 mg per day based on estimated glomerular filtration rate, or placebo (n = 155) during mechanical ventilation up to a maximum of 15 days before gradual dose reduction over 3 to 6 days. MAIN OUTCOMES AND MEASURES: The primary end point was the percentage of patients with at least 1 agitation-related event over the treatment period. Secondary outcomes included duration of mechanical ventilation, length of ICU stay, and 28-day mortality. RESULTS: Among 314 patients who were randomized (mean age, 57 years; 60 [17.2%] women), 313 (99.7%) completed the trial. There was a statistically significant decrease in the percentage of patients who experienced at least 1 agitation-related event in the baclofen group vs the placebo group (31 [19.7%] vs 46 [29.7%]; difference, -9.93% [95% CI, -19.45% to -0.42%]; adjusted odds ratio, 0.59 [95% CI, 0.35-0.99]). Of 18 prespecified secondary end points, 14 were not significantly different. Compared with the placebo group, the baclofen group had a significantly longer median length of mechanical ventilation (9 vs 8 days; difference, 2.00 [95% CI, 0.00-3.00]; hazard ratio [HR] for extubation, 0.76 [95% CI, 0.60-0.97]) and stay in the ICU (14 vs 11 days; difference, 2.00 [95% CI, 0.00-4.00]; HR for discharge, 0.70 [95% CI, 0.54-0.90]). At 28 days, there was no significant difference in mortality in the baclofen vs placebo group (25.3% vs 21.6%; adjusted odds ratio, 1.24 [95% CI, 0.72-2.13]). Delayed awakening (no eye opening at 72 hours after cessation of sedatives and analgesics) occurred in 14 patients (8.9%) in the baclofen group vs 3 (1.9%) in the placebo group. CONCLUSIONS AND RELEVANCE: Among patients with unhealthy alcohol use receiving mechanical ventilation, treatment with high-dose baclofen, compared with placebo, resulted in a statistically significant reduction in agitation-related events. However, considering the modest effect and the totality of findings for the secondary end points and adverse events, further research is needed to determine the possible role of baclofen in this setting and to potentially optimize dosing. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02723383.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Vourc'h M, Garret C, Gacouin A, et al. Effect of High-Dose Baclofen on Agitation-Related Events Among Patients With Unhealthy Alcohol Use Receiving Mechanical Ventilation: A Randomized Clinical Trial. JAMA. 2021. PMID: 33620407. doi:10.1001/jama.2021.0658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。